Thetis reports data supporting it IBD candidate

Thetis Pharmaceuticals reports preclinical data supporting the potential of its lead candidate, TP-317, in inflammatory bowel disease (IBD).

TP-317 is a novel salt of Resolvin E1 (RvE1) being developed as a potential first-in-class, safe, oral agent for treatment of ulcerative colitis and Crohn’s disease. more